Overview
Recumed develops medical tools combining human biology with neural networks, including a telerehabilitation platform with an EMG sensor band developed in 2017–2019. It also researches COPD diagnosis using salivary biomarkers and a set of tests for rapid COPD detection.
Financials
Revenue history (in k)
Filing timeliness
5 of 6 financial statements were filed late (the longest delay 787 days for 2022).
- 2025filed
- 202417/06/2026
- 202310/09/2025
- 202209/09/2025
- 202128/11/2022
- 202027/04/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Offer
- Biomarker research
- COPD diagnostics
- Telerehabilitation platform
- EMG signal analysis
- Medical software
Website technology
- Website
- Next.js
Trademarks
Recumed currently holds no active trademarks with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2020.
| Mark | Protected until | |
|---|---|---|
| recumed | – |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Marcin Moździerskiage 46 | 850 | $11,480.28 | 85% |
Tomasz Rogowskiage 47 | 150 | $2,025.93 | 15% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2017-05-13.
77 1020 1169 0000 8402 0247 1902
Debt
No entries in the National Debtors Register (KRZ).
Public aid
8 public aid cases recorded, with a total value of $1,142,503.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 3, 2021 | Aid for research and development projects: industrial research | $560.1K$560,073 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 3, 2021 | Aid for research and development projects: experimental development | $470.3K$470,283 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 3, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $79,886$79,886 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-05-01 | Development of a new test kit for the rapid diagnosis of chronic obstructive pulmonary disease using CRP, PCT, NE and AAT measured in saliva | $1.1M$1,102,824 | Operational Programme Smart Growth | |
| 2017-03-20 | Development, through research and development work, of an innovative rehabilitation platform by Recumed Sp. z o.o. | $928.6K$928,574 | Regional Operational Programme – Lubuskie 2020 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Prophasesp. z o.o. | $80,481.99 | prophase.eu | ||
| Polmedi Groupsp. z o.o. | $78,388.92 | polmedi.com | ||
| Wellsisp. z o.o. | $77,570.50 | wellsi.app | ||
| 2R Systemssp. z o.o. | $70,179.02 | 2rsystems.pl | ||
| Revotech Prosp. z o.o. | $69,210.21 | revotech-pro.com | ||
| Neuradetectsp. z o.o. | $63,227.80 | neuradetect.com | ||
| Algomedicasp. z o.o. | $48,251.24 | algomedica.tech | ||
| Komiressp. z o.o. | $48,217.23 | komires.pl | ||
| Prym-Softsp. z o.o. | $28,306.20 | prym-soft.pl | ||
| OWL Iotsp. z o.o. | $13,561.02 | owliot.pl |
FAQ
Last updated: 2026-06-17